A cost-effectiveness analysis of four management strategies in the determination and follow-up of atypical squamous cells of undetermined significance

Diagnostic Cytopathology

Volumn 32, Issue 2, 2005, Pages 125-132

  Hughes, Alice A ^a,c   Glazner, Judith ^a   Barton, Phoebe ^a   Shlay, Judith C ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^c MC 0180 ^*  (United States)

Author keywords

ASCUS; Conventional cytology; Cost effectiveness; Human papilliomavirus; Liquid based cytology

Indexed keywords

ADULT; ATYPICAL SQUAMOUS CELL OF UNDETERMINED SIGNIFICANCE; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; CYTOPATHOLOGY; FEMALE; FOLLOW UP; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL; VIRUS IDENTIFICATION; WART VIRUS;

ADOLESCENT; ADULT; AGED; COST-BENEFIT ANALYSIS; DIAGNOSTIC ERRORS; FEMALE; GENITAL DISEASES, FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS; WOMEN'S HEALTH;

EID: 12744262856     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20210     Document Type: Review

References (52)

1. Myers ER, McCory DC, Subramanian S, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol 2000;96:645-652.
2. Cantor SB, Mitchell MF, Tortolero-Luna G, et al. Cost-effectiveness analysis of diagnosis and management of cervical squamous intraepithelial lesions. Obstet Gynecol 1998;91:270-277.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
4. Taylor LA, Sorenson SV, Ray NF, Halpern MT, Harper DM. Cost-effectiveness of the conventional Papanicolaou test with a new adjunct to cytology screening for squamous cell carcinoma of the uterine cervix and its precursors. Arch Fam Med 2000;9:713-721.
5. McCory D, Mather D, Bastian L, et al. Evidence report/technology assessment, number 5: evaluation of cervical cytology. 1999 AHCPR Publication 99-E010. Rockville MD: Agency for Health Care Policy and Research; AHCPR, 1999.
6. Van Oortmarssen GJ, Habbema JDF. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative Pap smears. Int J Epidemiol 1995;24:300-307.
7. Chesebro ML, Everette WD. A cost-benefit analysis of colposcopy for cervical squamous intraepithelial lesions found on Papanicolaou smear. Arch Fam Med 1996;5:576-581.
8. Myers ER, McCrory DC, Nanda K, Bastian L, Marchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-1171.
9. Eddy DM. Screening for cervical cancer. Ann Int Med 1990;113:214-2266.
10. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytology abnormalities. JAMA 2002;287:2120-2129.
11. Montz FJ, Farber KM, Bristow RE, Cornelison T. The impact of increasing Pap sensitivity and compliance: a modeled cost and outcome analysis. Obstet Gynecol 2001;97:781-787.
12. Surveillance, epidemiology, end results (SEER) cancer statistics review 1973-1999. Available at www.seer.cancer.gov. Accessed December 15, 2001.
13. Manderblatt JS, Lawerance WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287: 2372-2381.
14. Jones BA, Davey DD. Quality management in gynecologic cytology using inter- laboratory comparison. Arch Pathol Lab Med 2000;124: 672-681.
15. Park IA, Lee SH, Chae SW, Park HW, Kim JW, Lee HP. Comparing the accuracy of ThinPrep Pap tests and conventional Papanicolaou smears on the basis of the histologic diagnosis: a clinical study of women with cervical cancer abnormalities. Acta Cytol 2001;45:525-531.
16. Hartmann KE, Nanda K, Hall S, Myers E. Technologic advances for evaluation of cervical cytology: is newer better? Obstet Gynecol Surv 2001;56:765-774.
17. Papillo JL, Zarka MA, St. John TL. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month 1,314 case experience in northern Vermont. Acta Cytol 1998;42:203-208.
18. Lee KR, Ashfaq R, Birdsong GG, Corkill ME, Mcintosh KM, Inhorn SL. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol 1997;90:278-284.
19. Bolick DR, Hellman DJ. Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer screening system. Acta Cytol 1998;42:209-213.
20. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human Papillomavirus testing women with atypia on Papanicolaou smears. Obstet Gynecol 2000;96:410-416.
21. Hutchinson ML, Berger BM, Farber FL. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity. Am J Manag Care 2000;6:766-780.
22. Raab SS, Zaleski S, Silverman JF. The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention. Anal Pathol 1999;111:259-266.
23. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human Papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-1610.
24. Soloman D, Schiffman M, Tarone R. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-1392.
25. Wright TC, Lorincz A, Ferris DG, et al. Reflex human Papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998;178:962-966.
26. Wright TC, Xiao WS, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologie abnormalities. Obstet Gynecol 1995;85:202-210.
27. Raab SS, Steiner AL, Hornberger J. The cost-effectiveness of treating women with cervical vaginal smear diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1998;179: 411-420.
28. Monk BJ, Brewster WR. Does the ALTS trial apply to the community-based practitioner? Am J Obstet Gynecol 2003;188:1381-1382.
29. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-3115.
30. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human Papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-1757.
31. Gamzu R, Almog B, Levin I, et al. Clinical and economic implications of adding HPV tests to the routine cytology follow-up and management of patients with histologically defined cervical intraepithelial neoplasia grade 1. Gynecol Oncol 2002;86:129-133.
32. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-2390.
33. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308-317.
34. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 1999;281:347-353.
35. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114-2119.
36. Vooijs G. Benign proliferative reactions, intraepithelial neoplasia and invasive cancer of the uterine cervix. In: Bibbo M, editor. Comparative cytopathology. Philadelphia; WB Saunders; 1991. p 153-230.
37. Kirschner CG, Anderson CA, Beebe M, et al. Current procedural terminology CPT 2001. Chicago, IL AMA press; 2001. p 229-267.
38. Gallagher PE, Klemp T, Smith SL. Medicare RBRVS: the physicians guide 2002. Chicago, IL. AMA Press; 2002. p 276-431.
39. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologie diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995; 172:946-954.
40. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human Papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23:333-341.
41. Montz FJ, Monk BJ, McCabe F, Nguyen L. Natural history of the minimally abnormal Papanicolaou smear. Obstet Gynecol 1992;80: 385-388.
42. Smith WJ. The cost-effectiveness of cervical screening. Curr Opin Obstet Gynecol 1999;11:83-85.
43. Johnson N, Sutton J, Thornton JG, Lilford RJ, Johnson VA, Peel KR. Decision analysis for best management of mildly dyskaryotic smear. Lancet 1993;342:91-96.
44. van Ballegooijen M, Habbema J, van Oortmarssen G, Koopmanschap M, Lubbe J, van Agt H. Br J Cancer 1992;65:930-933.
45. Van Oortmarssen G, Habbema J. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 64:559-565.
46. Herrero R, Hildesheim A, Bratt C, et al. Population-based study of human Papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-474.
47. Keating JT, Wang HH. Significance of a diagnosis of atypical squamous cells of undetermined significance for Papanicolaou smears in perimenopausal and postmenopausal women. Cancer 2001;93:100-105.
48. Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998;92:737-744.
49. Lytwyn A, Gafni A, Sellers JW, et al. Economic evaluation of hybrid capture human Papillomavirus testing in women with low-grade Papanicolaou smear abnormalities. J Lower Genital Tract Dis 1998;2: 213-220.
50. Lazcano-Ponce E, Herrero R, Munoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-420.
51. Ferris DG, Wright TC, Litaker MS, et al. Triage of women with ASCUS and LSIL on Pap smear Reports: management by repeat Pap smear. HPV DNA testing, or colposcopy? J Fam Pract 1998;46:125-134.
52. Ferris DG, Wright TC, Litaker MS, et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract 1998;46:136-141.